Biosimilars Market Rapid Growth By Leading Players Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare, Eli Lilly.

Biosimilars are generally derived from living cells of plants, animals, yeast, bacteria and viruses, through genetic engineering processes including controlled gene expression and recombinant DNA technology. In 2010, the Food and Drug Administration (FDA) approved biosimilars as a part of Patient Protection and Affordable Care Act. The approval process is based on thorough demonstration of similarity and comparability with existing approved product.

For instance, in August 2016, the FDA approved Sandoz for the biosimilar Erelzi for treatment of multiple inflammatory diseases such as rheumatoid arthritis, plaque psoriasis, ankylosing spondylitis and juvenile idiopathic arthritis.

Download PDF Brochure of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-pdf/750

Biosimilars are biopharmaceutical drug having active components, which are similar to one that has previously been licensed. They are identical copies of the original products and can be manufactured only when the patent for the original innovator product expires. Biologics or biosimilars are sensitive to changes in manufacturing process due to the higher molecular complexity.

Increasing demand for cost-effective drugs, increasing number of geriatric population, high healthcare expenditure, increasing government support and initiatives to develop and promote biosimilars, strategic collaborations to enhance productivity and clinical trial for development of biosimilars are major factors driving growth of the market. According to the American Health and Drug Benefits in 2013, an estimated sale of biosimilars was more than US$ 1 billion annually. For instance, global sales of biosimilars was projected to reach US$ 7.19 billion for Remicade (infliximab) and US$ 5.98 billion for Avastin (bevacizumab), owing to high adoption of biosimilar drugs by doctors and patients.

Furthermore, expiry and termination of pharmaceuticals drugs such as Humira, Enbrel and Remicade is providing significant opportunity for new players to enter the market.
Regional segmentation of the biosimilars market by Coherent Market Insights comprises North America, Europe, Asia Pacific, Latin America, Middle East, and Africa. The first biosimilar, Sandoz’s Zarxio was approved by FDA in 2015 for sale in North America. According to the American Society of Health-System Pharmacists survey in 2013, around 99% of 214 surveyed pharmacy directors reported shortage of at least one oncologic drug with distribution of biosimilars. Also, biosimilars market in North America region is expected to gain significant traction, owing to increasing prevalence of cancer, autoimmune diseases, kidney failures, and growth hormone deficiency. Biosimilar drugs provide cost effective treatment options for various diseases such as diabetes, rheumatoid arthritis and cancer, thus providing opportunities for growth of market in China and India. Furthermore, biosimilars market in Asia Pacific region is expected to witness higher growth, availability of cost effective biosimilars, high adoption rate, and consistent guidelines issued by regulatory bodies.

Competitive Analysis

Key players operating in the biosimilars market include Sandoz International GmbH, Apotex, Biocon, Zydus Cadila Healthcare, Celltrion, Pfizer, Hexal, Accord Healthcare, Harvest Moon Pharmaceuticals, Eli Lilly, and Teva Pharmaceuticals. Leading manufacturers are focusing on outsourcing the production of biosimilar drugs with strategic collaborations to replace existing drugs.

Request For Customization Of This Business Research Report: https://www.coherentmarketinsights.com/insight/request-customization/750

Biosimilars Market Taxonomy

The global biosimilars market is segmented on the basis of product type, manufacturing type, application, end user, and geography.

On the basis of product type, the global biosimilars market is segmented into:
Monoclonal Antibodies
Recombinant Hormones
Anti-Inflammatory Agents
Recombinant Growth Stimulators
Immunomodulators

On the basis of by manufacturing type, the global biosimilars market is segmented into:
In-house Manufacturing
Contract Manufacturing Organizations

On the basis of application, the global biosimilars market is segmented into:
Chronic & Autoimmune Diseases
Oncology
Blood Disorders
Growth Hormone Deficiency Diseases
Infectious Diseases
Others

About Coherent Market Insights:

Coherent Market Insights is a prominent market research and consulting firm offering action-ready syndicated research reports, custom market analysis, consulting services, and competitive analysis through various recommendations related to emerging market trends, technologies, and potential absolute dollar opportunity.

1001 4th Ave,, #3200, Seattle, WA 98154

This release was published on openPR.